Intellia Therapeutics/$NTLA
1D1W1MYTD1Y5YMAX
About Intellia Therapeutics
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
- Ticker
- $NTLA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 377
- Headquarters
- Cambridge, United States
- Website
- www.intelliatx.com
NTLA Metrics
BasicAdvanced
$1.8B
-
-$3.34
1.79
-
Price and volume
Market cap
$1.8B
Beta
1.79
52-week high
$28.25
52-week low
$7.95
Average daily volume
3.4M
Financial strength
Current ratio
6.648
Quick ratio
5.606
Long term debt to equity
6.88
Total debt to equity
10.088
Profitability
EBITDA (TTM)
-414.4
Gross margin (TTM)
-374.44%
Net profit margin (TTM)
-672.16%
Operating margin (TTM)
-711.66%
Revenue per employee (TTM)
$160,000
Management effectiveness
Return on assets (TTM)
-30.14%
Return on equity (TTM)
-55.44%
Valuation
Price to revenue (TTM)
25.605
Price to book
2.45
Price to tangible book (TTM)
2.45
Price to free cash flow (TTM)
-4.37
Free cash flow yield (TTM)
-22.88%
Free cash flow per share (TTM)
-2.916
Growth
Revenue change (TTM)
12.58%
Earnings per share change (TTM)
-28.59%
3-year revenue growth (CAGR)
3.91%
10-year revenue growth (CAGR)
20.31%
3-year earnings per share growth (CAGR)
-14.98%
10-year earnings per share growth (CAGR)
-3.01%
What the Analysts think about NTLA
Analyst ratings (Buy, Hold, Sell) for Intellia Therapeutics stock.
NTLA Financial Performance
Revenues and expenses
NTLA Earnings Performance
Company profitability
NTLA News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.